GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Theriva Biologics Inc (FRA:SFY) » Definitions » EV-to-FCF

Theriva Biologics (FRA:SFY) EV-to-FCF : 0.38 (As of May. 15, 2024)


View and export this data going back to . Start your Free Trial

What is Theriva Biologics EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Theriva Biologics's Enterprise Value is €-6.53 Mil. Theriva Biologics's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2024 was €-17.03 Mil. Therefore, Theriva Biologics's EV-to-FCF for today is 0.38.

The historical rank and industry rank for Theriva Biologics's EV-to-FCF or its related term are showing as below:

FRA:SFY' s EV-to-FCF Range Over the Past 10 Years
Min: -30.33   Med: -1.01   Max: 2.65
Current: 0.38

During the past 13 years, the highest EV-to-FCF of Theriva Biologics was 2.65. The lowest was -30.33. And the median was -1.01.

FRA:SFY's EV-to-FCF is ranked better than
80.42% of 378 companies
in the Biotechnology industry
Industry Median: 7.545 vs FRA:SFY: 0.38

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-05-15), Theriva Biologics's stock price is €0.327. Theriva Biologics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 was €-1.071. Therefore, Theriva Biologics's PE Ratio for today is At Loss.


Theriva Biologics EV-to-FCF Historical Data

The historical data trend for Theriva Biologics's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Theriva Biologics EV-to-FCF Chart

Theriva Biologics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.62 -1.47 2.31 1.59 0.57

Theriva Biologics Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
EV-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.03 0.63 0.95 0.57 0.30

Competitive Comparison of Theriva Biologics's EV-to-FCF

For the Biotechnology subindustry, Theriva Biologics's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Theriva Biologics's EV-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Theriva Biologics's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where Theriva Biologics's EV-to-FCF falls into.



Theriva Biologics EV-to-FCF Calculation

Theriva Biologics's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=-6.529/-17.028
=0.38

Theriva Biologics's current Enterprise Value is €-6.53 Mil.
Theriva Biologics's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-17.03 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Theriva Biologics  (FRA:SFY) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Theriva Biologics's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=0.327/-1.071
=At Loss

Theriva Biologics's share price for today is €0.327.
Theriva Biologics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-1.071.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


Theriva Biologics EV-to-FCF Related Terms

Thank you for viewing the detailed overview of Theriva Biologics's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Theriva Biologics (FRA:SFY) Business Description

Traded in Other Exchanges
Address
9605 Medical Center Drive, Suite 270, Rockville, MD, USA, 20850
Theriva Biologics Inc is a clinical-stage pharmaceutical company developing a novel oncolytic adenovirus (OV) platform to address devastating cancers with high unmet needs. It is a lead clinical-stage program VCN-01, designed to break down the tumor stroma, and its preclinical-stage program VCN-11, leverages its proprietary Albumin Shield Technology to protect systemically administered oncolytic viruses from the host immune system.

Theriva Biologics (FRA:SFY) Headlines

From GuruFocus

SOFI WEALTH, LLC Goes on Buying Spree in 2nd Quarter

By GuruFocus Research GuruFocus Editor 07-25-2022